PL2651436T3 - Kompozycja antygenów mykobakteryjnych - Google Patents

Kompozycja antygenów mykobakteryjnych

Info

Publication number
PL2651436T3
PL2651436T3 PL11794778.8T PL11794778T PL2651436T3 PL 2651436 T3 PL2651436 T3 PL 2651436T3 PL 11794778 T PL11794778 T PL 11794778T PL 2651436 T3 PL2651436 T3 PL 2651436T3
Authority
PL
Poland
Prior art keywords
antigenic composition
mycobacterium
mycobacterium antigenic
composition
antigenic
Prior art date
Application number
PL11794778.8T
Other languages
English (en)
Inventor
Stephane Andre Georges Godart
Amina Laanan
Dominique Ingrid Lemoine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2651436T3 publication Critical patent/PL2651436T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/5695Mycobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
PL11794778.8T 2010-12-14 2011-12-14 Kompozycja antygenów mykobakteryjnych PL2651436T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14

Publications (1)

Publication Number Publication Date
PL2651436T3 true PL2651436T3 (pl) 2016-10-31

Family

ID=45346501

Family Applications (3)

Application Number Title Priority Date Filing Date
PL11794778.8T PL2651436T3 (pl) 2010-12-14 2011-12-14 Kompozycja antygenów mykobakteryjnych
PL15201196T PL3023106T3 (pl) 2010-12-14 2011-12-14 Kompozycja antygenów mykobakteryjnych
PL11799673T PL2651437T3 (pl) 2010-12-14 2011-12-14 Kompozycja antygenów mykobakteryjnych

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL15201196T PL3023106T3 (pl) 2010-12-14 2011-12-14 Kompozycja antygenów mykobakteryjnych
PL11799673T PL2651437T3 (pl) 2010-12-14 2011-12-14 Kompozycja antygenów mykobakteryjnych

Country Status (32)

Country Link
US (5) US9730992B2 (pl)
EP (4) EP3593813A1 (pl)
JP (2) JP5951634B2 (pl)
KR (3) KR20140029376A (pl)
CN (4) CN106822882A (pl)
AR (1) AR084285A1 (pl)
AU (2) AU2011343368C1 (pl)
BR (2) BR112013014599A2 (pl)
CA (2) CA2819298A1 (pl)
CO (2) CO6751287A2 (pl)
CY (1) CY1122187T1 (pl)
DK (3) DK2651437T3 (pl)
EA (2) EA027504B1 (pl)
ES (3) ES2567190T3 (pl)
HR (3) HRP20160362T1 (pl)
HU (3) HUE045766T2 (pl)
IL (2) IL226450A0 (pl)
LT (1) LT3023106T (pl)
ME (1) ME02380B (pl)
MX (2) MX344280B (pl)
MY (1) MY161412A (pl)
PL (3) PL2651436T3 (pl)
PT (2) PT2651436E (pl)
RS (1) RS54687B1 (pl)
SG (2) SG190731A1 (pl)
SI (3) SI3023106T1 (pl)
SM (1) SMT201600118B (pl)
TW (1) TW201305192A (pl)
UA (2) UA110806C2 (pl)
UY (1) UY33802A (pl)
WO (2) WO2012080369A1 (pl)
ZA (2) ZA201304015B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5164830B2 (ja) 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
MY161412A (en) 2010-12-14 2017-04-14 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
HUE032409T2 (en) 2011-01-04 2017-09-28 Archivel Farma Sl Liposome preparation for treating or preventing tuberculosis
PT2802345T (pt) 2012-01-12 2018-04-24 Archivel Farma Sl Vacina mtb-c contra a asma
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN113046312A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
JP7136777B2 (ja) 2016-12-07 2022-09-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規プロセス
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
MX2021001129A (es) 2018-07-31 2021-07-02 Glaxosmithkline Biologicals Sa Metodo de purificacion de antigenos.
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20210069321A1 (en) 2019-09-09 2021-03-11 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
MX2022013855A (es) 2020-05-05 2022-11-30 Glaxosmithkline Biologicals Sa Dispositivos de mezcla de microfluidos y metodos de uso.
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
WO2022122830A2 (en) 2020-12-09 2022-06-16 Glaxosmithkline Biologicals Sa Saponins
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
IL123506A (en) 1995-09-01 2004-12-15 Corixa Corp Polypeptide compounds and preparations for immunotherapy and diagnosis of tuberculosis
ATE324445T1 (de) 1995-09-01 2006-05-15 Corixa Corp Verbindungen und verfahren zur diagnose von tuberkulose
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
KR20010006169A (ko) * 1997-04-08 2001-01-26 폴락 돈나 엘. 안정화된 사람 파필로마바이러스 제형물
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AU753995B2 (en) 1998-04-07 2002-10-31 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO1999052549A1 (en) * 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
WO2001024820A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ATE442866T1 (de) 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
AU8189501A (en) 2000-06-29 2002-01-08 Smithkline Beecham Biolog Vaccine composition
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
JP5164830B2 (ja) * 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
EP2368568A1 (en) 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
CA2687632C (en) 2007-05-24 2013-01-15 Glaxosmithkline Biologicals S.A. Lyophilised antigen composition
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
KR100955470B1 (ko) * 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
US8409901B2 (en) 2008-03-11 2013-04-02 The Royal Institution For The Advancement Of Learning/Mcgill University Low temperature wafer level processing for MEMS devices
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
MY161412A (en) 2010-12-14 2017-04-14 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
EA201390631A1 (ru) 2014-11-28
EP3593813A1 (en) 2020-01-15
PT3023106T (pt) 2019-11-04
US20130287809A1 (en) 2013-10-31
KR20190022897A (ko) 2019-03-06
AU2011343367A1 (en) 2013-07-11
SI2651437T1 (sl) 2016-05-31
SI3023106T1 (sl) 2019-11-29
CO6751288A2 (es) 2013-09-16
CA2819298A1 (en) 2012-06-21
US9730992B2 (en) 2017-08-15
US20190183998A1 (en) 2019-06-20
UA110806C2 (uk) 2016-02-25
JP2013545783A (ja) 2013-12-26
KR101951894B1 (ko) 2019-02-26
PL3023106T3 (pl) 2019-12-31
CO6751287A2 (es) 2013-09-16
EA201390630A1 (ru) 2013-12-30
KR20130124525A (ko) 2013-11-14
HRP20191843T1 (hr) 2019-12-27
UA110118C2 (uk) 2015-11-25
IL226448A0 (en) 2013-07-31
EP2651437A1 (en) 2013-10-23
SMT201600118B (it) 2016-07-01
MX2013006818A (es) 2013-08-26
AU2011343368C1 (en) 2015-12-24
RS54687B1 (en) 2016-08-31
MX344706B (es) 2017-01-03
CN103260642B (zh) 2018-03-16
CN103249431A (zh) 2013-08-14
ES2574403T3 (es) 2016-06-17
JP2014505036A (ja) 2014-02-27
SG190731A1 (en) 2013-07-31
EA027504B1 (ru) 2017-08-31
MY161412A (en) 2017-04-14
WO2012080369A1 (en) 2012-06-21
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
ZA201304014B (en) 2017-04-26
EP2651436A1 (en) 2013-10-23
EP2651437B1 (en) 2016-02-10
EP3023106B1 (en) 2019-07-31
ZA201304015B (en) 2018-12-19
CN106822883A (zh) 2017-06-13
AU2011343368A1 (en) 2013-07-11
SI2651436T1 (sl) 2016-07-29
JP5951634B2 (ja) 2016-07-13
ES2748651T3 (es) 2020-03-17
LT3023106T (lt) 2019-10-25
CA2819297A1 (en) 2012-06-21
PL2651437T3 (pl) 2016-07-29
DK2651437T3 (en) 2016-05-02
UY33802A (es) 2012-07-31
HUE027932T2 (en) 2016-11-28
BR112013014599A2 (pt) 2016-09-27
ES2567190T3 (es) 2016-04-20
IL226450A0 (en) 2013-07-31
PT2651436E (pt) 2016-06-08
AU2011343368B2 (en) 2015-08-20
DK3023106T3 (da) 2019-09-30
US20130280289A1 (en) 2013-10-24
IL226448A (en) 2017-09-28
MX2013006819A (es) 2013-08-26
US20160220656A1 (en) 2016-08-04
CY1122187T1 (el) 2020-11-25
JP5951633B2 (ja) 2016-07-13
MX344280B (es) 2016-12-09
EP3023106A1 (en) 2016-05-25
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
CN103249431B (zh) 2016-11-02
US20180071378A1 (en) 2018-03-15
AU2011343367B2 (en) 2015-05-21
SG190937A1 (en) 2013-07-31
EP2651436B1 (en) 2016-03-30
AR084285A1 (es) 2013-05-08
CN106822882A (zh) 2017-06-13
TW201305192A (zh) 2013-02-01
DK2651436T3 (da) 2016-06-20
WO2012080370A1 (en) 2012-06-21
BR112013014598A2 (pt) 2017-09-19
KR20140029376A (ko) 2014-03-10
CN103260642A (zh) 2013-08-21
HUE028452T2 (en) 2016-12-28
EA027920B1 (ru) 2017-09-29
HRP20160606T1 (hr) 2016-07-01
US9352030B2 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
ZA201304015B (en) Mycobacterium antigenic composition
GB201003924D0 (en) Immunogenic composition
GB201002983D0 (en) Nutritinal composition
GB201006699D0 (en) Composition
GB201015132D0 (en) Vaccine composition
ZA201208093B (en) Mycobacterial antigen composition
GB201006178D0 (en) Composition
EP2609931A4 (en) IMMUNOGENIC COMPOSITION
GB201017048D0 (en) Composition
GB201016970D0 (en) Composition
GB201005927D0 (en) Improved composition
GB201007531D0 (en) Composition
GB201006214D0 (en) Composition
GB201006204D0 (en) Composition
GB201004717D0 (en) Composition
GB201010657D0 (en) Composition
GB201006175D0 (en) Composition
GB201014967D0 (en) Composition
GB201006182D0 (en) Composition
GB201006012D0 (en) Composition
GB201002356D0 (en) Composition
GB201003918D0 (en) Immunogenic composition
GB201006369D0 (en) Polysiloxane composition
GB201012820D0 (en) Composition
GB201011487D0 (en) composition